{"name": "Prexa Pharmaceuticals",
 "permalink": "prexa-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/prexa-pharmaceuticals",
 "homepage_url": "http://www.prexainc.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2006,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "egraham@prexainc.com",
 "phone_number": "203.858.3428 ",
 "description": "",
 "created_at": "Sat Apr 30 01:59:55 UTC 2011",
 "updated_at": "Thu May 12 03:13:36 UTC 2011",
 "overview": "\u003Cp\u003EPrexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson\u00e2\u20ac\u2122s disease.\u003C/p\u003E\n\n\u003Cp\u003EPrexa\u00e2\u20ac\u2122s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa\u00e2\u20ac\u2122s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa\u00e2\u20ac\u2122s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       97],
      "assets/images/resized/0013/2675/132675v1-max-150x150.png"],
     [[250,
       162],
      "assets/images/resized/0013/2675/132675v1-max-250x250.png"],
     [[253,
       164],
      "assets/images/resized/0013/2675/132675v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman/CEO ",
    "person":
     {"first_name": "Charlie",
      "last_name": "Cohen",
      "permalink": "charlie-cohen",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Ev",
      "last_name": "(Evelyn) Graham",
      "permalink": "ev-evelyn-graham",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$10.2M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/04/25/daily70-Prexa-Pharma-raises-32M-to-target-ADHD-depression-Parkinsons.html",
    "source_description": "Prexa Pharma raises $3.2M to target ADHD, depression, Parkinson's",
    "raised_amount": 3200000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 29,
    "investments":
     []},
   {"round_code": "b",
    "source_url": "http://www.prexainc.com/pdfs/prexa_051111.pdf",
    "source_description": "Prexa Pharmaceuticals Obtains $7.0 million in Series B Financing",
    "raised_amount": 7000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 5,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Advent Venture Partners",
         "permalink": "advent-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0001/6550/16550v3-max-150x150.png"],
             [[250,
               100],
              "assets/images/resized/0001/6550/16550v3-max-250x250.png"],
             [[450,
               181],
              "assets/images/resized/0001/6550/16550v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company":
        {"name": "Shire",
         "permalink": "shire",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-150x150.png"],
             [[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-250x250.png"],
             [[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-450x450.png"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "184 High Street ",
    "address2": "",
    "zip_code": "02110",
    "city": "Boston",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}